Failure to Obtain Informed Consent for Psychotropic Medications
Summary
The facility failed to inform residents and/or their representatives, in advance, of the risks and benefits of proposed psychotropic medications before beginning treatment for four sampled residents. The facility’s policy stated that before initiating or increasing a psychotropic medication, the resident or legal representative would be fully informed of the proposed treatment, including risks, benefits, and alternatives, and that documentation of informed consent would be maintained for all psychotropic medications prescribed. Resident #4 had diagnoses including schizoaffective disorder, generalized anxiety disorder, bipolar disorder, and insomnia, and the quarterly MDS showed severe cognitive impairment with antipsychotic, antianxiety, and antidepressant use. The POS listed lorazepam, risperidone, trazodone, haloperidol, and Uzedy, but the record only contained a psychotropic consent for a haloperidol dose decrease; there were no psychotropic consents for lorazepam, risperidone, trazodone, or Uzedy. Resident #10 had dementia with behavioral disturbances, cerebral infarction, mild cognitive impairment, and depression, and the MDS showed moderately impaired cognition with antipsychotic use. The POS included Seroquel as needed and quetiapine at bedtime, but there was no documentation that consents or education about risks and benefits were provided to the resident or representative. Resident #27 had bipolar disorder and anxiety disorder, with severe cognitive impairment on the quarterly MDS and antipsychotic and antidepressant use in the lookback period. The POS listed aripiprazole and escitalopram, but there was no documentation of psychotropic consents or that risks and benefits were provided. Resident #46 had bipolar disorder, schizoaffective disorder, major depressive disorder, anxiety disorder, PTSD, and borderline personality disorder, with moderately impaired cognition on the quarterly MDS and antipsychotic, antianxiety, and antidepressant use. The POS listed Depakote, fluoxetine, haloperidol, and Seroquel, but there was no documentation of consents or education of risks and benefits for Depakote, Seroquel, or haloperidol. Staff interviews showed RN A believed consents were only needed for new medications started in the facility or dose changes, and the DON stated the facility had not been completing psychotropic medication consents for all residents receiving these medications.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release August 26, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.